Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

Publisher： John Wiley & Sons Inc

E-ISSN： 2326-5205|70|1|60-68

ISSN： 2326-5191

Source： ARTHRITIS & RHEUMATOLOGY, Vol.70, Iss.1, 2018-01, pp. : 60-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical experience with infliximab biosimilar in psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : e347-e348

John Wiley & Sons Inc

Access to resources Recommend Favorite

Infliximab biosimilar CT‐P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : e325-e326

John Wiley & Sons Inc

Access to resources Recommend Favorite

Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 356-363

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study

By Bingham Clifton O.   Ince Akgun   Haraoui Boulos   Keystone Edward C.   Chon Yun   Baumgartner Scott  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1131-1142

Informa Healthcare

Access to resources Recommend Favorite

Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’’s disease in children: REACH open-label extension

By Hyams Jeffrey   Walters Thomas D.   Crandall Wallace   Kugathasan Subra   Griffiths Anne   Blank Marion   Johanns Jewel   Lang Yinghua   Markowitz James   Cohen Stanley   Winter Harland S.   Veereman-Wauters Gigi   Ferry George   Baldassano Robert  

Current Medical Research and Opinion, Vol. 27, Iss. 3, 2011-03 ,pp. : 651-662

Informa Healthcare

Access to resources Recommend Favorite